Stevanato Group (STVN) Competitors

Stevanato Group (NYSE:STVN) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation, community ranking and media sentiment.

Does the media refer more to STVN or ZBH?

In the previous week, Zimmer Biomet had 9 more articles in the media than Stevanato Group. MarketBeat recorded 12 mentions for Zimmer Biomet and 3 mentions for Stevanato Group. Zimmer Biomet's average media sentiment score of 1.11 beat Stevanato Group's score of 1.05 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in STVN or ZBH?

88.9% of Zimmer Biomet shares are held by institutional investors. 0.7% of Stevanato Group shares are held by insiders. Comparatively, 1.0% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has higher valuation & earnings, STVN or ZBH?

Zimmer Biomet has higher revenue and earnings than Stevanato Group. Zimmer Biomet is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	$1.17B	5.34	$157.62M	$0.47	44.06
Zimmer Biomet	$7.68B	2.72	$903.70M	$4.45	23.57

Which has more risk and volatility, STVN or ZBH?

Stevanato Group has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.

Do analysts prefer STVN or ZBH?

Zimmer Biomet has a consensus price target of $124.15, suggesting a potential upside of 18.36%. Given Zimmer Biomet's higher possible upside, analysts plainly believe Zimmer Biomet is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Zimmer Biomet	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.32

Does the MarketBeat Community favor STVN or ZBH?

Zimmer Biomet received 875 more outperform votes than Stevanato Group when rated by MarketBeat users. Likewise, 67.06% of users gave Zimmer Biomet an outperform vote while only 63.04% of users gave Stevanato Group an outperform vote.

Company	Underperform	Outperform
Stevanato Group	Outperform Votes 29 63.04%	Underperform Votes 17 36.96%
Zimmer Biomet	Outperform Votes 904 67.06%	Underperform Votes 444 32.94%

Is STVN or ZBH more profitable?

Zimmer Biomet has a net margin of 11.77% compared to Stevanato Group's net margin of 10.47%. Zimmer Biomet's return on equity of 12.99% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	10.47%	9.86%	5.79%
Zimmer Biomet	11.77%	12.99%	7.58%

Summary

Zimmer Biomet beats Stevanato Group on 15 of the 18 factors compared between the two stocks.